Pfizer (PFE) and Astellas Pharma (ALPMY) "announced positive topline results from the Phase 3 EMBARK trial evaluating XTANDI in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. Patients enrolled in the trial were randomized to one of three study arms: XTANDI plus leuprolide, placebo plus leuprolide, or XTANDI monotherapy. The study met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival for patients treated with XTANDI plus leuprolide versus placebo plus leuprolide. At the time of the analysis, a positive trend in the key secondary endpoint of overall survival (OS) was also observed, but these data were not yet mature. Patients in the trial will be followed for a subsequent final OS analysis. The study also met a key secondary endpoint with a statistically significant and clinically meaningful improvement in MFS for patients treated with XTANDI monotherapy versus placebo plus leuprolide. Additional key secondary endpoints reached statistical significance, including time to prostate-specific antigen progression and time to first use of new antineoplastic therapy. Other secondary endpoints are being analyzed. No new safety signals have been observed to date in the preliminary safety analysis, which is consistent with the established safety profile of XTANDI."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer says continues to gather pediatric data on Paxlovid
- FDA advisory committee votes in support of safety and effectiveness of Paxlovid
- FDA advisors back full approval for Pfizer’s Paxlovid in 16-1 vote
- Pfizer recalls Nurtec ODT on packaging issues, risk of poisoning
- Royalty Pharma raises FY23 adjusted cash receipt guidance to $2.85B-$2.95B